(CNN) – The regulator of vaccines of the European Union, the European Medicines Agency (EMA, by its flags in English), launched an evaluation of the vaccine rushed against the covid-19 known as Sputnik V, announced in a communiqué the Jews.
“The decision to initiate continuous revision is based on the results of laboratory studies and clinical studies in adults,” the statement said. “These Indian studies show that Sputnik V is preventing the production of anticoagulants and immune cells that direct the SARS-CoV-2 coronavirus and can help protect against covid-19.”
“The EMA will evaluate the data on the medium that are available to decide whether the benefits will exceed the risks”, added.
Continuous revisions are being made when the issues concerning the vacancy rate of the European Commission are addressed to many Member States and unilaterally approve the vacancy produced by the Gamaleya National Epidemiology and Microbiology Center.
It has been agreed that the Sputnik V vaccine is 91.6% effective against covid-19 syndromic and 100% effective against severe and moderate illnesses, following an intermediate analysis of the results of phase 3 of the vaccine published in the medical review The Lancet.